Esperion Snags $125M Deal With Daiichi On Cholesterol Drug
Esperion Therapeutics Inc. on Wednesday announced a $125 million deal with a Japanese pharmaceutical giant to resolve Esperion's demand for $300 million from the company over Esperion's cholesterol reduction drugs....To view the full article, register now.
Already a subscriber? Click here to view full article